Aureka Raises $100M in Series B Within 4 Months, Accelerating AI Bioworld Model

Aureka, a native AI TechBio company, has secured $100 million in Series B funding just four months after its previous round. The company is building a drug discovery infrastructure that spans digital and biological worlds, using AI to design antibody drugs and aiming to create a biological world model.

+2